GBP Serves as a Novel Prognostic Biomarker in Human Glioblastoma

The most frequent primary intracranial tumors are gliomas. The malignancy of various tumor grades varies, and tumor heterogeneity is common. Despite the variety of therapeutic options available, most glioma patients still have a dismal prognosis, causing considerable pain to glioma sufferers throughout the world. The research of glioma's intrinsic disease processes and the development of new treatment targets are critical. The family's big GTPases, which are engaged in a variety of activities including cell inflammation, proliferation, and apoptosis, play a significant role in cancer. The goal of this work is to determine the mechanism of action of the GBPs family in glioblastoma and to provide a novel approach to glioma mechanistic research and therapy. We analyzed the mRNA expression, protein level expression, prognostic value, genetic changes, and immunological infiltration of the GBPs family in glioma patient tissues employing GEPIA2, Human Protein Atlas (HPA), cBio Portal, and TIMER databases. The effects of the essential gene GBP2 on tumor cell proliferation and invasion were also confirmed. Differential expression of the GBPs family was detected in GBM, with differential expression of GBP1 and GBP2 correlated with GBM patient prognosis. Besides this, we discovered that the GBPs family and associated genes are engaged in a variety of activities, including the cellular response to interferon−γ, GTP binding, endoplasmic reticulum architecture, and protein complex oligomerization. GBPs family gene expression is linked to tumor immune cell infiltration, and genetic variations in the gene can affect immune cell infiltration in GBM patients. GBP2 gene expression enhances tumor cell proliferation and invasion, according to further experimental confirmation. We investigated the role of GBPs in GBM and discovered that GBP1/2 are possible biomarkers for predicting prognosis and tumor immune infiltration in GBM patients, with GBP2 expression potentially contributing to the impact of tumor invasion and proliferative capability.